A Hyderabad-based startup is at the forefront of a new battle against cancer, developing experimental vaccines tailored to an individual’s tumour. This personalised approach could mark a pivotal shift in oncology, moving beyond one-size-fits-all treatments.
A New Era of Cancer Treatment
For decades, cancer treatment has relied on surgery, radiation, and chemotherapy—methods that can be effective but often damage healthy cells. The next frontier in oncology is far more precise. It involves training a patient's own immune system to identify and destroy cancer cells. This is the world of personalised cancer vaccines, a therapeutic, not preventative, treatment designed for a single individual. Unlike traditional vaccines that protect against infections, these are created after a cancer diagnosis to fight the disease from within, targeting unique markers on tumour cells called neoantigens.
The Science of 'Personalised' mRNA
At the heart of this innovation is messenger RNA (mRNA), the same technology that became globally recognised during the COVID-19 pandemic. Here's how it works for cancer: first, a patient's tumour is genetically sequenced to identify its unique mutations. Using artificial intelligence and machine learning, scientists at PopVax identify which of these mutations produce abnormal proteins, or neoantigens, that can act as 'flags' for the immune system. An mRNA vaccine is then designed with instructions to teach the body's cells how to create these specific flags. When injected, the vaccine prompts the immune system to hunt down and attack any cells that display them—that is, the cancer cells.
Meet Hyderabad's PopVax
Founded in 2021 by Soham Sankaran, PopVax has rapidly emerged as a key player in India's biotech landscape. What began as a two-person team in a small lab has grown into a 100-strong company with an integrated research and manufacturing facility in Hyderabad called the RNA Foundry. The company's name is short for 'population-scale vaccines', reflecting its mission to make cutting-edge medicines accessible globally. PopVax is backed by prominent investors, including the Bill & Melinda Gates Foundation and the US Biomedical Advanced Research and Development Authority (BARDA). While its cancer programme is in the R&D stage, the company is already running a clinical trial in Australia for a COVID-19 vaccine based on the same mRNA platform.
The Road Ahead: Challenges and Promise
Developing personalised cancer vaccines is a complex, resource intensive process. One of the biggest challenges is accurately predicting which neoantigens will trigger a strong immune response. Tumours themselves are complicated; they can have diverse mutations and create an environment that suppresses the immune system, potentially limiting a vaccine's effectiveness. Furthermore, the journey from lab to patient requires bespoke manufacturing for every single person, which is a major logistical and financial hurdle. PopVax has not yet administered its cancer vaccines to patients but aims to do so under compassionate use and named patient pathways, subject to regulatory approvals. The company is initially focusing on cancers with poor survival rates.
Why This Matters for India and the World
PopVax's work represents a significant step for India's ambition to become a global hub for biotech innovation, moving beyond its reputation as the 'pharmacy of the world' for generic medicines. By building a 'full stack' platform that combines AI driven design with in house manufacturing, the startup aims to accelerate the development of new treatments for cancer and infectious diseases like tuberculosis and malaria. A key innovation is their work on a thermostable mRNA formulation that can be stored in a regular refrigerator, removing the need for the ultra cold chains that limited the distribution of early COVID $19$ vaccines, particularly in lower income countries. This could prove crucial for making such advanced therapies more equitable and accessible worldwide.
